EA018989B1 - Производные 2,4-диоксотиазолидинилиденметана - Google Patents
Производные 2,4-диоксотиазолидинилиденметана Download PDFInfo
- Publication number
- EA018989B1 EA018989B1 EA201100119A EA201100119A EA018989B1 EA 018989 B1 EA018989 B1 EA 018989B1 EA 201100119 A EA201100119 A EA 201100119A EA 201100119 A EA201100119 A EA 201100119A EA 018989 B1 EA018989 B1 EA 018989B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- dione
- thiazolidine
- benzylidene
- thiazolidin
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7763908P | 2008-07-02 | 2008-07-02 | |
| US18327809P | 2009-06-02 | 2009-06-02 | |
| PCT/GB2009/050773 WO2010001169A2 (en) | 2008-07-02 | 2009-07-02 | Chemical compounds 251 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201100119A1 EA201100119A1 (ru) | 2011-08-30 |
| EA018989B1 true EA018989B1 (ru) | 2013-12-30 |
Family
ID=41050276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201100119A EA018989B1 (ru) | 2008-07-02 | 2009-07-02 | Производные 2,4-диоксотиазолидинилиденметана |
Country Status (27)
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116187C2 (uk) | 2005-12-13 | 2018-02-26 | Інсайт Холдінгс Корпорейшн | ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ |
| ES2714092T3 (es) | 2007-06-13 | 2019-05-27 | Incyte Holdings Corp | Uso de sales del inhibidor de quinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo |
| UY31952A (es) * | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
| TW201100429A (en) | 2009-05-22 | 2011-01-01 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| UA106078C2 (uk) | 2009-05-22 | 2014-07-25 | Інсайт Корпорейшн | 3-[4-(7H-ПІРОЛО[2,3-d]ПІРИМІДИН-4-ІЛ)-1H-ПІРАЗОЛ-1-ІЛ]ОКТАН- АБО ГЕПТАННІТРИЛ ЯК JAK-ІНГІБІТОРИ |
| WO2011028685A1 (en) | 2009-09-01 | 2011-03-10 | Incyte Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| TWI643857B (zh) | 2010-03-10 | 2018-12-11 | 英塞特公司 | 作為ｊａｋ１抑制劑之哌啶-４-基三亞甲亞胺衍生物 |
| PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
| JP5917545B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体 |
| WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| AR086983A1 (es) | 2011-06-20 | 2014-02-05 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TW201319063A (zh) * | 2011-10-04 | 2013-05-16 | Yakult Honsha Kk | 以四氫噻唑衍生物或其鹽為有效成分之醫藥品 |
| JP5386662B1 (ja) | 2012-03-30 | 2014-01-15 | ロート製薬株式会社 | 新規ベンジリデンアゾリジン誘導体またはその塩 |
| US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| WO2014007228A1 (ja) * | 2012-07-03 | 2014-01-09 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
| NZ748448A (en) | 2012-11-15 | 2019-12-20 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| KR102403306B1 (ko) | 2013-01-15 | 2022-06-02 | 인사이트 홀딩스 코포레이션 | Pim 키나제 저해제로서 유용한 티아졸카복스아마이드 및 피리딘카복스아마이드 화합물 |
| TWI634121B (zh) | 2013-03-06 | 2018-09-01 | 英塞特控股公司 | 用於製備ｊａｋ抑制劑之方法及中間物 |
| JP6378918B2 (ja) * | 2013-04-03 | 2018-08-22 | 株式会社ヤクルト本社 | チアゾリジン誘導体又はその塩を有効成分とするＰｉｍ阻害剤 |
| US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| KR20220103810A (ko) | 2013-08-07 | 2022-07-22 | 인사이트 코포레이션 | Jak1 억제제용 지속 방출 복용 형태 |
| JP2016528298A (ja) | 2013-08-23 | 2016-09-15 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用なフロピリジン及びチエノピリジンカルボキシアミド化合物 |
| WO2015046390A1 (ja) * | 2013-09-27 | 2015-04-02 | ロート製薬株式会社 | 新規ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物 |
| TW201601769A (zh) * | 2013-09-27 | 2016-01-16 | 樂敦製藥股份有限公司 | 皮膚外用組成物 |
| JPWO2015122504A1 (ja) * | 2014-02-13 | 2017-03-30 | 国立大学法人 東京大学 | キナーゼ阻害剤 |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| JP5857104B2 (ja) * | 2014-06-17 | 2016-02-10 | ロート製薬株式会社 | ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物 |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US10195189B2 (en) | 2014-12-15 | 2019-02-05 | Prosetta Antiviral, Inc. | 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds |
| CN105985298B (zh) * | 2015-02-10 | 2018-02-23 | 湖南大学 | 2‑[(5‑卤噻唑‑2‑基)亚氨基]‑5‑亚苄基噻唑啉酮及其制备方法与应用 |
| MY190034A (en) | 2015-03-06 | 2022-03-22 | Beyondspring Pharmaceuticals Inc | Method of treating cancer associated with a ras mutation |
| CN106032365B (zh) * | 2015-03-11 | 2018-03-23 | 湖南大学 | 2‑(噻唑‑2‑基)亚氨基‑5‑亚苄基噻唑啉酮及其制备方法与应用 |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| PE20180528A1 (es) | 2015-07-13 | 2018-03-19 | Beyondspring Pharmaceuticals Inc | Composiciones de plinabulina |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| MX2018009413A (es) | 2016-02-08 | 2019-05-15 | Beyondspring Pharmaceuticals Inc | Composiciones que contienen tucaresol o sus analogos. |
| JP7116422B2 (ja) | 2016-04-05 | 2022-08-10 | イミューン センサー リミテッド ライアビリティ カンパニー | ｃＧＡＳアンタゴニスト化合物 |
| TWI777957B (zh) | 2016-06-06 | 2022-09-21 | 中國大陸商大連萬春布林醫藥有限公司 | 降低嗜中性白血球減少症之組合物及方法 |
| EP3468953B1 (en) | 2016-06-13 | 2024-05-22 | GlaxoSmithKline Intellectual Property Development Limited | Substituted pyridines as inhibitors of dnmt1 |
| EP3565812B1 (en) | 2017-01-06 | 2023-12-27 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| CN112739345A (zh) | 2017-11-06 | 2021-04-30 | 斯奈普生物公司 | Pim激酶抑制剂组合物，方法和其用途 |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| AU2019213665B2 (en) | 2018-01-30 | 2024-06-13 | Incyte Corporation | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| SI3773593T1 (sl) | 2018-03-30 | 2024-08-30 | Incyte Corporation | Zdravljenje hidradenitisa suppurative z zaviralci jak |
| EP3786163A4 (en) * | 2018-04-26 | 2021-12-29 | Medicinal Bioconvergence Research Center | Novel compound as mtor inhibitor and use thereof |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| WO2023039170A1 (en) * | 2021-09-09 | 2023-03-16 | Musc Foundation For Research Development | Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy |
| CN116354901B (zh) * | 2023-04-12 | 2024-04-26 | 郑州大学 | 一种噻唑烷二酮类化合物及其制备方法和应用 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH093067A (ja) * | 1995-06-16 | 1997-01-07 | Hisamitsu Pharmaceut Co Inc | 新規なピペリジン誘導体 |
| EP0976748A1 (en) * | 1997-01-31 | 2000-02-02 | Shionogi & Co., Ltd. | Pyrrolidine derivatives having phospholipase a2 inhibitory activity |
| WO2001034133A2 (en) * | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| US20020120144A1 (en) * | 2000-12-22 | 2002-08-29 | Tsutomu Akama | Telomerase inhibitors and methods of their use |
| WO2004093809A2 (en) * | 2003-04-18 | 2004-11-04 | Incyte San Diego Incorporated | Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases |
| WO2006069186A2 (en) * | 2004-12-22 | 2006-06-29 | The Ohio State Research Foundation | Small molecule bcl-xl/bcl-2 binding inhibitors |
| WO2009064486A2 (en) * | 2007-11-15 | 2009-05-22 | Musc Foundation For Research Development | Inhibitors of pim protein kinases, compositions, and methods for treating cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE62214B1 (en) * | 1988-05-25 | 1995-01-11 | Warner Lambert Co | Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents |
| IL113313A (en) * | 1994-04-11 | 1999-09-22 | Sankyo Co | Heterocyclic compounds and pharmaceutical compositions containing the same |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| EP0880508B1 (en) | 1996-02-13 | 2003-04-16 | AstraZeneca AB | Quinazoline derivatives as vegf inhibitors |
| IL125954A (en) | 1996-03-05 | 2003-06-24 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| UA56185C2 (uk) | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| ID29875A (id) * | 1999-07-01 | 2001-10-18 | Geron Corp Cs | Penghambat-penghambat telomerase dan metode penggunaannya |
| CN1155586C (zh) | 1999-08-23 | 2004-06-30 | 杏林制药株式会社 | 取代的苄基噻唑烷-2,4-二酮衍生物 |
| TW593293B (en) * | 1999-08-23 | 2004-06-21 | Kyorin Seiyaku Kk | Substituted benzylthiazolidine-2,4-dione derivatives |
| JP2003535078A (ja) | 2000-05-31 | 2003-11-25 | アストラゼネカ アクチボラグ | 血管損傷活性のあるインドール誘導体 |
| WO2002008213A1 (en) | 2000-07-07 | 2002-01-31 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
| RS115904A (en) | 2002-07-10 | 2006-12-15 | Applied Research Systems Ars Holding N.V. | Azolidinone-vinyl fused benzene derivatives |
| US7531556B2 (en) | 2004-04-28 | 2009-05-12 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| UY31952A (es) * | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
-
2009
- 2009-07-01 UY UY0001031952A patent/UY31952A/es not_active Application Discontinuation
- 2009-07-01 TW TW098122261A patent/TWI461423B/zh not_active IP Right Cessation
- 2009-07-02 AR ARP090102486A patent/AR072791A1/es unknown
- 2009-07-02 EA EA201100119A patent/EA018989B1/ru not_active IP Right Cessation
- 2009-07-02 WO PCT/GB2009/050773 patent/WO2010001169A2/en active Application Filing
- 2009-07-02 NZ NZ590859A patent/NZ590859A/xx not_active IP Right Cessation
- 2009-07-02 BR BRPI0914599A patent/BRPI0914599A2/pt not_active IP Right Cessation
- 2009-07-02 MX MX2010014233A patent/MX2010014233A/es active IP Right Grant
- 2009-07-02 CN CN200980134849.5A patent/CN102137666B/zh not_active Expired - Fee Related
- 2009-07-02 PE PE2010001221A patent/PE20120304A1/es not_active Application Discontinuation
- 2009-07-02 JP JP2011515631A patent/JP5261575B2/ja not_active Expired - Fee Related
- 2009-07-02 EP EP09772849A patent/EP2310010A2/en not_active Withdrawn
- 2009-07-02 CA CA2729557A patent/CA2729557A1/en not_active Abandoned
- 2009-07-02 KR KR1020117002754A patent/KR20110031367A/ko not_active Application Discontinuation
- 2009-07-02 AU AU2009265362A patent/AU2009265362B2/en not_active Ceased
- 2009-07-02 MY MYPI2010006322A patent/MY155961A/en unknown
- 2009-07-02 US US13/000,138 patent/US8901307B2/en not_active Expired - Fee Related
- 2009-07-02 CN CN201410037508.9A patent/CN103804371A/zh active Pending
-
2010
- 2010-12-20 IL IL210127A patent/IL210127A0/en unknown
- 2010-12-30 HN HN2010002786A patent/HN2010002786A/es unknown
- 2010-12-30 CL CL2010001636A patent/CL2010001636A1/es unknown
- 2010-12-30 EC EC2010010735A patent/ECSP10010735A/es unknown
- 2010-12-30 DO DO2010000408A patent/DOP2010000408A/es unknown
-
2011
- 2011-01-03 SV SV2011003786A patent/SV2011003786A/es unknown
- 2011-01-05 NI NI201100007A patent/NI201100007A/es unknown
- 2011-01-10 CR CR20110016A patent/CR20110016A/es unknown
- 2011-02-01 CO CO11011427A patent/CO6341555A2/es active IP Right Grant
- 2011-02-01 ZA ZA2011/00844A patent/ZA201100844B/en unknown
-
2013
- 2013-02-20 JP JP2013031176A patent/JP2013139459A/ja not_active Ceased
-
2014
- 2014-07-24 US US14/339,981 patent/US20150051185A1/en not_active Abandoned
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH093067A (ja) * | 1995-06-16 | 1997-01-07 | Hisamitsu Pharmaceut Co Inc | 新規なピペリジン誘導体 |
| EP0976748A1 (en) * | 1997-01-31 | 2000-02-02 | Shionogi & Co., Ltd. | Pyrrolidine derivatives having phospholipase a2 inhibitory activity |
| WO2001034133A2 (en) * | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| US20020120144A1 (en) * | 2000-12-22 | 2002-08-29 | Tsutomu Akama | Telomerase inhibitors and methods of their use |
| WO2004093809A2 (en) * | 2003-04-18 | 2004-11-04 | Incyte San Diego Incorporated | Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases |
| WO2006069186A2 (en) * | 2004-12-22 | 2006-06-29 | The Ohio State Research Foundation | Small molecule bcl-xl/bcl-2 binding inhibitors |
| WO2009064486A2 (en) * | 2007-11-15 | 2009-05-22 | Musc Foundation For Research Development | Inhibitors of pim protein kinases, compositions, and methods for treating cancer |
Non-Patent Citations (2)
| Title |
|---|
| OTTANA R. ET AL.: "In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidi nones. Part I" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB LNKD-DOI: 10.1016/J. BMCL. 2005.05.093, vol. 15, no. 17, 1 September 2005 (2005-09-01), pages 3930-3933, XP025314117 ISSN: 0960-894X [retrieved on 2005-09-01] the whole document page 3931; figure l, compound 4 * |
| XIA ZUPING ET AL.: "Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases". JOURNAL OF MEDICINAL CHEMISTRY 8 JAN 2009 LNKD-PUBMED: 19072652, vol. 52, no. 1, 8 January 2009 (2009-01-08), pages 74-86, XP002584626 ISSN: 1520-4804 the whole document page 78; table 3; compounds 6a, 7a * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA018989B1 (ru) | Производные 2,4-диоксотиазолидинилиденметана | |
| RU2525389C2 (ru) | Соединения, которые являются ингибиторами erk | |
| KR101014525B1 (ko) | 신규 화합물 | |
| EP2547664B1 (de) | Morpholinylchinazoline | |
| KR101084871B1 (ko) | 피라졸로-퀴나졸린 유도체, 그의 제조 방법 및 상기유도체의 키나제 저해제로서의 용도 | |
| RU2422449C2 (ru) | Фармацевтические соединения | |
| EP2468717B1 (en) | Heterocyclic Amide Compounds Useful as Kinase Inhibitors | |
| US8188101B2 (en) | Dihydropyridopyrimidines for the treatment of AB-related pathologies | |
| JP2021529740A (ja) | サイクリン依存性キナーゼの阻害剤 | |
| JP2011507908A (ja) | ベンゾフロピリミジノン | |
| WO2002062787A1 (en) | Pyrazoles as tgf inhibitors | |
| KR20190034620A (ko) | 피페리딘 cxcr7 수용체 조절제 | |
| KR102466810B1 (ko) | 포유류 티로신 키나제 ror1 활성의 저해제로서 유용한 2-페닐이미다조[4,5-b]피리딘-7-아민 유도체 | |
| AU2014234907B2 (en) | Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors | |
| JP2008501672A (ja) | ケモカイン受容体アンタゴニストとしてのチアゾール誘導体 | |
| AU616708B2 (en) | 4-heteropentacyclic-4-{n-(phenyl)amido}piperidine derivatives and pharmaceutical compositions and method employing such compounds | |
| KR101730205B1 (ko) | 신규 (헤테로사이클/테트라히드로피리딘)-(피페라지닐)-1-알카논 및 (헤테로사이클/디히드로피롤리딘)-(피페라지닐)-1-알카논유도체, 및 ｐ75 억제제로서의 그의 용도 | |
| US8318749B2 (en) | Quinazoline derivatives as NK3 receptor antagonists | |
| EP3587411B1 (en) | 1-(alpha-methylbenzyl)-5-(piperidinomethyl)imidazole derivatives and uses thereof for improving the pharmacokinetics of a drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KG MD TJ TM RU |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KZ |